EGFR-TKI re-administration after osimertinib failure in T790M mutation loss cases with re-biopsy
{{output}}
Data on the re-administration of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) after osimertinib failure in patients with T790M-positive non-small cell lung cancer (NSCLC) is limited. EGFR-TKI re-administration efficacy may vary bet... ...
